Status of Product Development

Progress with regenerative cell medicines currently in development

Cell drug Indication Research Nonclinical PHASE1 PHASE2 PHASE3
SB623 Traumatic brain injury(chronic) US
Ischemic stroke (chronic) US
Hemorrhagic stroke (chronic)       1
Dry age-related macular degeneration
Retinitis pigmentosa
Parkinson`s disease
Spinal cord injury
Alzheimer`s disease
SB618 Peripheral nerve damage, etc
SB308 Muscle dystrophy, etc
MSC1 Cancer
MSC2 Inflammatory disease
※1Clinical trials of Hemorrhagic stroke are expected to begin in Phase 2 or Phase 3. Expanded Access Program